Advances in GvHD: Current Treatments, Optimizing Prophylaxis, and Integrating Novel Therapies

Learn from the experts about current treatments prophylaxis and novel therapies to guide optimal GvHD treatment in your patients by watching this on-demand Webcast and downloading the slides including Clinical ExpressPoints slides.

Share

Program Content

Activities

GVHD Prophylaxis
Prevention and Prophylaxis of GVHD
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 02, 2020

Expires: December 01, 2021

Advances in aGVHD
Recent Advances in the Management of aGVHD
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 03, 2020

Expires: December 02, 2021

Advances in cGVHD
Recent Advances in the Management of cGVHD
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 03, 2020

Expires: December 02, 2021

EP: GVHD Management
ExpressPoints: Advances in the Management of GVHD
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2020

Expires: December 08, 2021

Activities

GVHD Management
Advances in GVHD: Current Treatments, Optimizing Prophylaxis, and Integrating Novel Therapies
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: December 08, 2020

Expires: December 07, 2021

Faculty

cover img faculity

Corey Cutler, MD, MPH, FRCPC

Associate Professor of Medicine
Harvard Medical School
Medical Director, Stem Cell Transplantation
Dana-Farber Cancer Institute
Boston, Massachusetts

cover img faculity

Nelson Chao, MD, MBA

Donald D. and Elizabeth G. Cooke Professor
Chief, Division of Hematology Malignancies and Cellular Therapy/BMT
Director, Global Cancer
Duke University
Durham, North Carolina

cover img faculity

David Miklos, MD, PhD

Professor of Medicine
Chief,
Blood Marrow Transplantation and Cancer Cell Therapy
Stanford University
Stanford, California

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Incyte Corporation